RxDoctor Payments Data

Kayla Cottrill

Nurse Practitioner · Warsaw, INNPI 1073992327

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 61 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$194
  • AbbVie$149
  • Boehringer Ingelheim$112
  • Dexcom, Inc.$105
  • AstraZeneca$93
  • Lilly USA, LLC$60
  • plus $300 from 12 others

What the payments were for

  • Food & beverage$1,011100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,011 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$40,459
Medicare patients
193
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$76,800
MounjaroTirzepatide57$73,950
JardianceEmpagliflozin69$64,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$29,647
EliquisApixaban25$27,051
LinzessLinaclotide17$18,058
Breo ElliptaFluticasone/Vilanterol20$15,038
MyrbetriqMirabegron15$9,687
FarxigaDapagliflozin Propanediol11$8,728
SymbicortBudesonide/Formoterol Fumarate15$3,870
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,565
Sumatriptan13$2,123
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,078
Omeprazole155$1,983
Albuterol Sulfate HfaAlbuterol Sulfate95$1,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$194$76,80052 claims
Lilly USA, LLCMounjaro$60$73,95057 claims
Boehringer IngelheimJardiance$112$64,06869 claims
GSKTrelegy Ellipta, Breo Ellipta$15$44,68545 claims
AbbVieLinzess$149$18,05817 claims
AstraZenecaFarxiga, Symbicort$93$12,59826 claims
Astellas Pharma US IncMyrbetriq$38$9,68715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →